The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells

International Journal of Molecular Medicine

Volumn 26, Issue 3, 2010, Pages 415-423

  Yoon, Jung Min ^a,b   Lee, Kyu Hwa ^a,b   Lee, Sang Min ^a,b   Lim, Jae Jun ^a,b   Yang, Seok Chul ^a,b   Yoo, Chul Gyu ^a,b   Lee, Choon Taek ^a,b   Han, Sung Koo ^a,b   Shim, Young Soo ^a,b   Kim, Young Whan ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Biomedical Research Institute   (South Korea)

Author keywords

Clara cell secretory protein; Cyclooxygenase 2; Immune modulation

Indexed keywords

CULTURE MEDIUM; CYTOKINE; SCGB1A1 PROTEIN, HUMAN; UTEROGLOBIN;

CELL CULTURE; CHEMISTRY; CHEMOTAXIS; CULTURE MEDIUM; CYTOLOGY; DENDRITIC CELL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; LUNG TUMOR; MONOCYTE; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELLS, CULTURED; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOMODULATION; LUNG NEOPLASMS; MONOCYTES; PHENOTYPE; UTEROGLOBIN;

EID: 77956707992     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000481     Document Type: Article

References (36)

1. Pockaj BA, Basu GD, Pathangey LB, et al: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 11: 328-339, 2004.
2. Kaufman HL and Disis ML: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 113: 664-667, 2004.
3. Marincola FM, Wang E, Herlyn M, Seliger B and Ferrone S: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24: 335-342, 2003.
4. Goto S, Sato M, Kaneko R, Itoh M, Sato S and Takeuchi S: Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48: 435-442, 1999. (Pubitemid 29503443)
5. Singh B and Lucci A: Role of cyclooxygenase-2 in breast cancer. J Surg Res 108: 173-179, 2002.
6. Singh-Ranger G and Mokbel K: The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 28: 729-737, 2002.
7. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002. (Pubitemid 34408488)
8. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
9. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140, 1996.
10. Stolina M, Sharma S, Lin Y, et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
11. Munkarah AR, Morris R, Baumann P, et al: Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 9: 168-173, 2002. (Pubitemid 34497146)
12. Amano H, Hayashi I, Endo H, et al: Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221-232, 2003.
13. Dohadwala M, Luo J, Zhu L, et al: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276: 20809-20812, 2001. (Pubitemid 37413056)
14. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289-293, 2002.
15. Harizi H, Juzan M, Pitard V, Moreau JF and Gualde N: Cyclooxygenase-2- issued prostaglandin E(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 168: 2255-2263, 2002. (Pubitemid 34171825)
16. Sharma S, Stolina M, Lin Y, et al: T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 163: 5020-5028, 1999.
17. Peri A, Cordella-Miele E, Miele L and Mukherjee AB: Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. J Clin Invest 92: 2099-2109, 1993. (Pubitemid 23333512)
18. Krishnan RS and Daniel JC Jr: 'Blastokinin': inducer and regulator of blastocyst development in the rabbit uterus. Science 158: 490-492, 1967.
19. Klug J, Beier HM, Bernard A, et al: Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Ann NY Acad Sci 923: 348-354, 2000.
20. Mandal AK, Zhang Z, Ray R, et al: Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions. J Exp Med 199: 1317-1330, 2004.
21. Mukherjee DC, Agrawal AK, Manjunath R and Mukherjee AB: Suppression of epididymal sperm antigenicity in the rabbit by uteroglobin and transglutaminase in vitro. Science 219: 989-991, 1983. (Pubitemid 13189534)
22. Levin SW, Butler JD, Schumacher UK, Wightman PD and Mukherjee AB: Uteroglobin inhibits phospholipase A2 activity. Life Sci 38: 1813-1819, 1986.
23. Lesur O, Bernard A, Arsalane K, et al: Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 152: 290-297, 1995.
24. Hicks SM, Vassallo JD, Dieter MZ, et al: Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology 187: 217-228, 2003.
25. Broers JL, Jensen SM, Travis WD, et al: Expression of surfactant associated protein-A and Clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab Invest 66: 337-346, 1992.
26. Lee JC, Park KH, Han SJ, et al: Inhibitory effect of adenovirus- uteroglobin transduction on the growth of lung cancer cell lines. Cancer Gene Ther 10: 287-293, 2003.
27. Yoon JM, Lim JJ, Yoo CG, et al: Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells. Lung Cancer 48: 201-209, 2005.
28. Roper RL and Phipps RP: Prostaglandin E2 regulation of the immune response. Adv Prostaglandin Thromboxane Leukot Res 22: 101-111, 1994.
29. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD and Kapsenberg ML: Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150: 5321-5329, 1993. (Pubitemid 23180645)
30. Misra N, Selvakumar M, Singh S, et al: Monocyte derived IL-10 and PGE2 are associated with the absence of Th 1 cells and in vitro T cell suppression in lepromatous leprosy. Immunol Lett 48: 123-128, 1995.
31. Sharma S, Stolina M, Yang SC, et al: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9: 961-968, 2003.
32. Yang SC, Hillinger S, Riedl K, et al: Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10: 2891-2901, 2004.
33. Yang SC, Batra RK, Hillinger S, et al: Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 66: 3205-3213, 2006.
34. Schuler G, Schuler-Thurner B and Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15: 138-147, 2003. (Pubitemid 36287518)
35. Ye Q, Fujita M, Ouchi H, et al: Serum CC-10 in inflammatory lung diseases. Respiration 71: 505-510, 2004.
36. Chen J, Lam S, Pilon A, McWilliams A, Melby J and Szabo E: The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial. Cancer Epidemiol Biomarkers Prev 16: 577-583, 2007. (Pubitemid 46548664)